Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for challenging cancers.
The partnership integrates Leveragen's Singularity Sapiens Mouse platform with the T-cell engineering expertise of Moonlight Bio, aiming to improve the efficacy, persistence and functionality of the therapies, particularly for solid tumours.
Leveragen will take charge of discovering fully human single-domain antibodies against therapeutic targets and the preclinical development of the T-cell therapies will be managed by Moonlight Bio.
Moonlight Bio chief scientific officer Jordan Jarjour stated: “At Moonlight Bio, we are dedicated to delivering T-cell therapies that break through barriers obstructing successful outcomes in solid tumours – the vast majority of the global cancer disease burden.
“Leveragen’s Singularity Sapiens Mouse platform is a powerful tool for generating fully human single-domain antibodies with properties that could optimally translate into advanced T-cell therapies, particularly when combined with the tools and technologies that the Moonlight Bio team is advancing.”
The Singularity Sapiens Mouse platform is engineered to produce chain-only antibodies derived from the entire human VH repertoire, incorporated directly into the mouse genome.
It optimises the development of B cells and produces immune responses.
This speeds up the discovery of therapeutic modalities such as messenger ribonucleic acid-based treatments, antibody-drug conjugates, the chimeric antigen receptor-T and bispecifics.
Leveragen founder and CEO Weisheng Chen stated: “Through this partnership with Moonlight Bio, we are combining our state-of-the-art antibody discovery platform with their advanced cell engineering capabilities to develop T cell therapies that have the potential to make a meaningful difference for patients.”
Based in Seattle, Washington, Moonlight Bio aims to develop potency-enhanced T-cell therapies, offering new hope to cancer patients.
In July 2024, Leveragen made a research, option and licence agreement with Moderna to advance the development of various therapeutics.
